Shanghai Rightongene Biotechnology Stock Revenue
| 688217 Stock | 19.59 0.26 1.31% |
Shanghai Rightongene Biotechnology fundamentals help investors to digest information that contributes to Shanghai Rightongene's financial success or failures. It also enables traders to predict the movement of Shanghai Stock. The fundamental analysis module provides a way to measure Shanghai Rightongene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Rightongene stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 296.9 M | 333.1 M |
Shanghai | Revenue |
Shanghai Rightongene Biotechnology Company Revenue Analysis
Shanghai Rightongene's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Shanghai Rightongene Revenue | 258.21 M |
Most of Shanghai Rightongene's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Rightongene Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Shanghai
Projected quarterly revenue analysis of Shanghai Rightongene provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Shanghai Rightongene match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Shanghai Rightongene's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Shanghai Total Revenue
Total Revenue |
|
Based on the latest financial disclosure, Shanghai Rightongene Biotechnology reported 258.21 M of revenue. This is 96.61% lower than that of the Biotechnology sector and 65.24% lower than that of the Health Care industry. The revenue for all China stocks is 97.26% higher than that of the company.
Shanghai Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Rightongene's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shanghai Rightongene could also be used in its relative valuation, which is a method of valuing Shanghai Rightongene by comparing valuation metrics of similar companies.Shanghai Rightongene is currently under evaluation in revenue category among its peers.
Shanghai Fundamentals
| Return On Equity | -0.0148 | ||||
| Return On Asset | -0.0097 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 894.28 M | ||||
| Shares Outstanding | 55.86 M | ||||
| Shares Owned By Insiders | 40.37 % | ||||
| Shares Owned By Institutions | 13.66 % | ||||
| Price To Book | 1.18 X | ||||
| Price To Sales | 4.39 X | ||||
| Revenue | 258.21 M | ||||
| Gross Profit | 182.74 M | ||||
| EBITDA | 25.94 M | ||||
| Net Income | 7.93 M | ||||
| Total Debt | 5.82 M | ||||
| Book Value Per Share | 14.70 X | ||||
| Cash Flow From Operations | 45.1 M | ||||
| Earnings Per Share | (0.10) X | ||||
| Number Of Employees | 501 | ||||
| Beta | 0.2 | ||||
| Market Capitalization | 1.09 B | ||||
| Total Asset | 1.04 B | ||||
| Retained Earnings | 154.03 M | ||||
| Working Capital | 467.29 M | ||||
| Net Asset | 1.04 B |
About Shanghai Rightongene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Rightongene Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Rightongene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Rightongene Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Other Information on Investing in Shanghai Stock
Shanghai Rightongene financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Rightongene security.